CN106890225A - A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application - Google Patents
A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application Download PDFInfo
- Publication number
- CN106890225A CN106890225A CN201710156866.5A CN201710156866A CN106890225A CN 106890225 A CN106890225 A CN 106890225A CN 201710156866 A CN201710156866 A CN 201710156866A CN 106890225 A CN106890225 A CN 106890225A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- blood lipid
- reducing blood
- preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application.The pharmaceutical composition of described reducing blood lipid includes 100~300 parts of raw hawthorn, 100~200 parts of raw sangqi ginseng, 50~150 parts of the Radix Polygoni Multiflori of parts by weight of raw materials, is prepared through pre-treatment, extraction and post-processing step.Preparation be described reducing blood lipid pharmaceutical composition in add tablet, powder, capsule, granule and pill prepared by pharmaceutically acceptable auxiliary material.Using application of the pharmaceutical composition for described reducing blood lipid in blood lipid-lowering medicine is prepared.Primary crude drug of the invention is autonomic drug, is the Chinese medicine of medicine-food two-purpose, and have existed since ancient times, for Drug safety provides optimal guarantee, also for the medicament research and development for the treatment of by Chinese herbs hyperlipidemia opens new world.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, system
Agent and application.
Background technology
Hyperlipemia refer to fat metabolism or operating is abnormal make blood plasma in one or more lipids higher than normal, can show
For hypercholesterolemia, hypertriglyceridemia or both have concurrently (combined hyperlipidemia familial).Lipid is insoluble or poorly soluble in water, must
Must be combined with protein and be existed in the form of lipoprotein, could be operated in blood circulation, therefore hyperlipemia Chang Weigao lipoprotein
The reflection of mass formed by blood stasis.
When hyperlipidemia blood fat (cholesterol and triglycerides etc.) increases, a large amount of lipid depositions form spot on vascular wall
Block, makes intravascular space narrow, vascular wall becomes fragile, and this is the main cause of atherogenesis.And atherosclerosis is
The pathogenesis basis of the diseases such as high blood pressure, coronary heart disease, Acute myocardial stalk, cerebral hemorrhage, cerebral infarction, ischemic enteropathy.These diseases
It is the common disease and frequently-occurring disease of the elderly, the incidence of disease and disability rate are all very high.And early stage is without any subjective symptoms, patient also like
Normal person is the same.Therefore it endangers the health of patient quietly just as noiseless killer and invisible moth.
Population of China blood fat average level is less than developed country, but its elevation amplitude is very surprising.China is to different regions 9
Group crowd, 20 years from early 1980s to the end of the nineties carry out 3 times than sex investigation, as a result show the total courage of serum
Sterol (TG) ＞ 5.20mmol/L (200mg/dl), male's illness rate continuously rises to 33% by 17%, and women illness rate is by 9%
Continuously rise to 32%.Therefore, actively detection, prevention and control dyslipidemia turn into developed area angiocarpy prevention work
One of main contents.
Conventional lipid-lowering medicine may occur in which that transaminase rising, DOMS, SCK are raised while reducing blood lipid,
The symptoms of digestive tract such as kidney function damage, rhabdomyolysis, n and V, abdominal distension, people are highly desirable to be found safely and effectively
Lipid-lowering medicine, treatment of motherland's medical science to hyperlipidemia is that based on traditional diagnosis and treatment, the deagnostic test with modern medicine is
Foundation, macroscopical differentiation of disease and microcosmic syndrome differentiation are combined, and give full play to the advantage that traditional Chinese medicine is integrally nursed one's health, and especially have in traditional Chinese medicine
The Chinese medicine of many medicine-food two-purposes, there is preferable preventive and therapeutic effect to hyperlipidemia patient, significantly improves curative effect, can long-term taking,
Have no side effect.For the treatment of this disease provides abundant theory and practice basis, here it is Technology origin of the invention.
The content of the invention
The first object of the present invention is to provide a kind of pharmaceutical composition of reducing blood lipid；Second purpose is described in offer
The preparation method of the pharmaceutical composition of reducing blood lipid；3rd purpose is the preparation of the pharmaceutical composition of the reducing blood lipid described in offer；
4th purpose is the application of the pharmaceutical composition of the reducing blood lipid described in offer.
The first object of the present invention is achieved in that the pharmaceutical composition of described reducing blood lipid includes parts by weight of raw materials
100~300 parts of raw hawthorn, 100~200 parts of raw sangqi ginseng, 50~150 parts of Radix Polygoni Multiflori, through pre-treatment, extract and post-processing step
Prepare.
The second object of the present invention is achieved in that including pre-treatment, extracts and post-processing step, specifically includes：
A, selected and clean bulk drug, are then uniformly mixed so as to obtain material a standby by formulation ratio weighing bulk drug；
B, alcohol solution dipping 7~10 days will be added in material a, be filtrated to get filtrate b and filter residue c；
C, the water of 8~12 times of filter residue c weight will be added to boil in filter residue c carry 3~4 times, every time 0.5~1.5h, merging filtrate,
It is concentrated to give thick paste d；
D, filtrate b is concentrated to give thick paste e, thick paste d and thick paste e are well mixed, drying and crushing sieving obtains object
The pharmaceutical composition of reducing blood lipid.
The third object of the present invention is achieved in that in the pharmaceutical composition of described reducing blood lipid to add and can pharmaceutically connect
Tablet, powder, capsule, granule and pill prepared by the auxiliary material received.
The fourth object of the present invention is achieved in that the pharmaceutical composition of described reducing blood lipid is preparing blood lipid-lowering medicine
In application.
It has been recognised by the inventors that hyperlipidemia is equivalent to motherland's medical science " phlegm wet ", " turbid resistance " category.Traditional Chinese medicine thinks its morbidity machine
Reason is that on the basis of qi of zang-fu viscera void declines, eating and drinking without temperance, quiet, addiction delicious food, the seven feelings internal lesions caused by overexertion etc. of sitting straight well form body ressitance weakened while pathogenic factors prevailing
It is caused.The interpretation of the cause, onset and process of an illness is visceral dysfunction, cereal nutrient dysfunction of the spleen in transportation and transformation, make that raw phlegm is turbid, hemostasis and cause blood fat to raise.Disease located in liver,
Spleen, kidney, disease and evil duty in phlegm-blood stasis.Treatment emphatically from liver spleen kidney opinion control, and then combine dialectical medication, dietotherapy, healthy Lifestyle,
Discontinue the habit of smoking and drinking, appropriate body building is in interior comprehensive prevention and the scheme for the treatment of hyperlipidemia.
Raw hawthorn digestion gathered food, scattered blood stasis in side of the present invention.Treatment meat product, phlegm and retained fluid, modern pharmacological research has the work of reducing blood lipid
With；Raw sangqi ginseng, hemostasis dissipates the stasis of blood；Radix Polygoni Multiflori filling liver kidney, blood-nourishing, modern pharmacology research prompting has obvious fat-reducing effect；This
Outward, prescription primary crude drug is the product of medicine-food two-purpose, and using safety, conjunction side " lipid-loweringing dissipates " all medicine joints, synergy plays work altogether
Blood stagnation resolvation, the work(of the lipid-loweringing that helps digestion is clinically used for the treatment of hyperlipidemia.
Raw hawthorn in prescription of the present invention,【Base】It is rosaceous plant hawthorn or the fruit of fructus crataegi cuneatae.【Meridian distribution of property and flavor】Acid
It is sweet, tepor.Enter spleen, stomach, Liver Channel.【Indication】Digestion gathered food, scattered blood stasis.Treatment meat Ji , Disorder lumps in the abdomen, phlegm and retained fluid, feeling of fullness, acid regurgitation etc.,
Modern pharmacological research plays the role of reducing blood lipid.
Raw sangqi ginseng,【Base】It is the root of Araliaceae Panax pseudoginseng.【Meridian distribution of property and flavor】Sweet slight bitter, temperature.Return liver, stomach, greatly
Intestines are passed through.【Indication】Hemostasis, dissipates the stasis of blood, and detumescence, analgesic therapy is treated to fall and flutters hemostasis, carbuncle swells pain etc..
Radix Polygoni Multiflori,【Base】It is the root tuber of polygonum multiflorum thunb.【Meridian distribution of property and flavor】Bitter sweet is puckery, tepor.Return liver, kidney
Through.【Indication】Tonifying liver, kidney-nourishing, blood-nourishing, wind-dispelling.Treatment liver-kidney Yin deficiency, hair must be early white, and the deficiency of blood is dizzy, and waist and knee is weak, muscles and bones
Ache, pass out semen, collapse band, chronic malaria etc., modern pharmacology research shows, the fleece-flower root has functions that reducing blood lipid.
The invention has the advantages that：
Inventor is observed by the clinical application over 6 years, and 115 " hyperlipidemia " patients are included altogether carries out clinical sight
Examine, pharmaceutical composition of the present invention can obvious reduction blood fat, to hypercholesterolemia, hypertriglyceridemia and mixed type hyperlipemia
Disease has an obvious therapeutic effect, clinical observation, and up to 96.00%, the primary crude drug of preparation is autonomic drug to its therapeutic effect, is
The Chinese medicine of medicine-food two-purpose, have existed since ancient times, is also treatment by Chinese herbs hyperlipidemia for Drug safety provides optimal guarantee
Medicament research and development open new world.
Specific embodiment
With reference to embodiment, the present invention is further illustrated, but the present invention is any limitation as never in any form,
Based on present invention teach that any conversion or replacement made, belong to protection scope of the present invention.
The pharmaceutical composition of reducing blood lipid of the present invention includes 100~300 parts of raw hawthorn, the raw sangqi ginseng of parts by weight of raw materials
100~200 parts, 50~150 parts of Radix Polygoni Multiflori, prepare through pre-treatment, extraction and post-processing step.
Raw hawthorn 100~300 part of the pharmaceutical composition of described reducing blood lipid including parts by weight of raw materials, raw sangqi ginseng 100~
200 parts, 50~150 parts of Radix Polygoni Multiflori, prepare through pre-treatment, extraction and post-processing step.
The preparation method of the pharmaceutical composition of reducing blood lipid of the present invention, including pre-treatment, extraction and post-processing step,
Specifically include：
A, selected and clean bulk drug, are then uniformly mixed so as to obtain material a standby by formulation ratio weighing bulk drug；
B, alcohol solution dipping 7~10 days will be added in material a, be filtrated to get filtrate b and filter residue c；
C, the water of 8~12 times of filter residue c weight will be added to boil in filter residue c carry 3~4 times, every time 0.5~1.5h, merging filtrate,
It is concentrated to give thick paste d；
D, filtrate b is concentrated to give thick paste e, thick paste d and thick paste e are well mixed, drying and crushing sieving obtains object
The pharmaceutical composition of reducing blood lipid.
The concentration expressed in percentage by volume of the ethanol solution described in step B is 60~80%.
The concentration expressed in percentage by volume of described ethanol solution is 70%.
The temperature soaked in step B is 20~40 DEG C.
Pulverizing and sieving described in D steps is to crush 200 mesh sieves.
The preparation of the pharmaceutical composition of reducing blood lipid of the present invention be described reducing blood lipid pharmaceutical composition in add
Tablet, powder, capsule, granule and pill prepared by pharmaceutically acceptable auxiliary material.
The application of the pharmaceutical composition of reducing blood lipid of the present invention is prepared by the pharmaceutical composition of described reducing blood lipid
Application in blood lipid-lowering medicine.
Method concrete operations prepared by the pharmaceutical composition of reducing blood lipid of the present invention are as follows：
(1) selected and clean medicine used, weighs raw hawthorn, raw sangqi ginseng, Radix Polygoni Multiflori, adds 70% ethanol immersion 7
Filter within~10 days to obtain alcohol liquid, alcohol liquid is concentrated under reduced pressure to obtain thick paste.
(2) the remaining dregs of a decoction of step (1) are added water to boil and is carried 3-4 times, 1 hour every time, filtrate was collected in filtering, is concentrated to give thick
Cream.
(3) thick paste obtained by step (1) and (2) is well mixed, dry, pulverize to obtain semi-finished product powder.
(4) semi-finished product are dispensed into obtain finished product, packing specification is 6g/ bags, and 100g/ bottles, every gram of finished product is equivalent to primary crude drug
10 grams.
(5) application method and the course for the treatment of：Warm water takes, each 6g, and 3 times a day, per 30 days as one therapeutic course.
So that case is embodied, the present invention will be further described below：
Embodiment 1
Raw material raw hawthorn 100g, raw sangqi ginseng 100g, Radix Polygoni Multiflori 50g are taken, adds the volume basis of 5 times of raw material gross weight dense
The ethanol solution of degree 80%, in being soaked 10 days at 20 DEG C of temperature, is filtrated to get filtrate and filter residue, and filtrate is concentrated to give thick paste e；Filter
Add the water of 12 times of filter residue to boil in slag to carry 4 times, 1 hour every time, filtrate was collected in filtering, thick paste d is concentrated to give, by thick paste d and thick paste
E is well mixed and crushed the pharmaceutical composition that 200 mesh sieves obtain object reducing blood lipid.
Embodiment 2
Raw material raw hawthorn 300g, raw sangqi ginseng 200g, Radix Polygoni Multiflori 150g are taken, the volume basis of 3 times of raw material gross weight are added
The ethanol solution of concentration 60%, in being soaked 10 days at 40 DEG C of temperature, is filtrated to get filtrate and filter residue, and filtrate is concentrated to give thick paste e；
Add the water of 8 times of filter residue to boil in filter residue and carry 3 times, 1 hour every time, filtrate was collected in filtering, is concentrated to give thick paste d, by thick paste d and thick
Cream e is well mixed and crushed the pharmaceutical composition that 200 mesh sieves obtain object reducing blood lipid.
Embodiment 3
Raw material raw hawthorn 200g, raw sangqi ginseng 150g, Radix Polygoni Multiflori 100g are taken, the volume basis of 4 times of raw material gross weight are added
The ethanol solution of concentration 70%, in being soaked 8 days at 30 DEG C of temperature, is filtrated to get filtrate and filter residue, and filtrate is concentrated to give thick paste e；
Add the water of 10 times of filter residue to boil in filter residue and carry 4 times, 1 hour every time, filtrate was collected in filtering, is concentrated to give thick paste d, by thick paste d and thick
Cream e is well mixed and crushed the pharmaceutical composition that 200 mesh sieves obtain object reducing blood lipid.
Embodiment 4
Raw material raw hawthorn 200g, raw sangqi ginseng 100g, Radix Polygoni Multiflori 80g are taken, adds the volume basis of 5 times of raw material gross weight dense
The ethanol solution of degree 80%, in being soaked 7 days at 40 DEG C of temperature, is filtrated to get filtrate and filter residue, and filtrate is concentrated to give thick paste e；Filter
Add the water of 8 times of filter residue to boil in slag to carry 4 times, 1 hour every time, filtrate was collected in filtering, thick paste d is concentrated to give, by thick paste d and thick paste e
It is well mixed to crush the pharmaceutical composition that 200 mesh sieves obtain object reducing blood lipid.
Embodiment 5
Raw material raw hawthorn 250g, raw sangqi ginseng 150g, Radix Polygoni Multiflori 100g are taken, the volume basis of 3 times of raw material gross weight are added
The ethanol solution of concentration 60%, in being soaked 10 days at 40 DEG C of temperature, is filtrated to get filtrate and filter residue, and filtrate is concentrated to give thick paste e；
Add the water of 12 times of filter residue to boil in filter residue and carry 4 times, 1 hour every time, filtrate was collected in filtering, is concentrated to give thick paste d, by thick paste d and thick
Cream e is well mixed and crushed the pharmaceutical composition that 200 mesh sieves obtain object reducing blood lipid.
Embodiment 6
Raw material raw hawthorn 200g, raw sangqi ginseng 150g, Radix Polygoni Multiflori 90g are taken, adds the volume basis of 4 times of raw material gross weight dense
The ethanol solution of degree 70%, in being soaked 7 days at 30 DEG C of temperature, is filtrated to get filtrate and filter residue, and filtrate is concentrated to give thick paste e；Filter
Add the water of 10 times of filter residue to boil in slag to carry 4 times, 1 hour every time, filtrate was collected in filtering, thick paste d is concentrated to give, by thick paste d and thick paste
E is well mixed and crushed the pharmaceutical composition that 200 mesh sieves obtain object reducing blood lipid.
Embodiment 7
Pharmaceutically acceptable auxiliary material is added to prepare in the pharmaceutical composition of the reducing blood lipid prepared with embodiment 2 in blocks
Agent.
Embodiment 8
Pharmaceutically acceptable auxiliary material is added to prepare plastic in the pharmaceutical composition of the reducing blood lipid prepared with embodiment 1
Wafer.
Embodiment 9
Pharmaceutically acceptable auxiliary material is added to be prepared into the pharmaceutical composition of the reducing blood lipid prepared with embodiment 4
Granula.
Embodiment 10
Pharmaceutically acceptable auxiliary material is added to prepare pelletization in the pharmaceutical composition of the reducing blood lipid prepared with embodiment 6
Agent.
Embodiment 11
The pharmaceutical composition for being prepared with 1~embodiment of embodiment 6 respectively carries out clinical test, and therapeutic effect reaches
96.00%.It is described further with part real case below：
Patient makes certain, man, 32 years old, trade, smoking 10 years, daily 20, height 1.72m, body weight 85KG, and patient is because of " hair
Existing Hyperlipidemia 20 days " is medical, and ferritic is healthy, and CHO (T-CHOL) is pointed out in physical examination before 20 days：8.8mmol/L, TG (glycerine three
Ester)：6.80mmol/L, diagnosis：Combined hyperlipidemia familial.Strict smoking cessation is advised, the medicine that the embodiment of the present invention 1 is prepared is taken
Composition, each 6g, 3 times a day, blood fat is checked after January and is shown：CHO (T-CHOL)：7.8mmol/L, TG (triglycerides)：
5.60mmol/L, patient reacts without discomfort, advises the same following the service, balanced diet, strengthens motion exercise, positive control body weight, periodically
Follow-up.
Patient Cao, man, 50 years old, peasant, height 1.60m, body weight 60KG deny special hobby, because " it was found that coronary artery is athero-
Patch first quarter moon " is gone to a doctor, and ferritic is healthy, and lipid examination shows：CHO (T-CHOL)：8.0mmol/L, TG (triglycerides)：
6.20mmol/L.Coronary artery color ultrasound shows that Atherosclerotic Vessels: Changes Observed during Coronary is formed.Diagnosis：1. combined hyperlipidemia familial；2. coronary artery congee
Sample patch is formed.Take the pharmaceutical composition that the embodiment of the present invention 2 is prepared, each 6g, 3 times a day, and blood fat is checked after January
Show：CHO (T-CHOL)：7.0mmol/L, TG (triglycerides)：5.10mmol/L, patient reacts without discomfort, advises the same following the service,
Balanced diet, strengthens motion exercise, monitors body weight, and treatment is checked after 2 months and shown：CHO (T-CHOL)：6.5mmol/L, TG are (sweet
Oily three esters)：4.50mmol/L, regular follow-up.
Patient for certain, female, 36 years old, office worker, height 1.55m, body weight 45KG, the greasy diet of eating, because " it was found that Hyperlipidemia
1 week " it is medical, the past body is good for, patient before 1 week physical examination show CHO (T-CHOL)：5.0mmol/L, TG (triglycerides)：
7.20mmol/L, it is remaining without exception.Diagnosis：Hypertriglyceridemia.Balanced diet is advised, strengthens motion exercise, take of the invention real
Apply the pharmaceutical composition that example 4 is prepared, each 6g, 3 times a day, blood fat is checked after January and is shown：CHO (T-CHOL)：
4.8mmol/L, TG (triglycerides)：6.00mmol/L, patient reacts without discomfort, advises the same following the service, strengthens motion exercise, monitoring
Body weight, treatment is checked after 2 months and shown：CHO (T-CHOL)：4.6mmol/L, TG (triglycerides)：5.00mmol/L, advises continuation same
Before take, uncomfortable follow-up, regular follow-up.
The present invention is not limited to the above embodiments, simply illustrates of the invention described in above-described embodiment and specification
Principle, without departing from the spirit and scope of the present invention, various changes and modifications of the present invention are possible, and these change and change
Enter all fall within the protetion scope of the claimed invention.The claimed scope of the invention is by appending claims and its equivalent
Define.
Claims (9)
1. a kind of pharmaceutical composition of reducing blood lipid, it is characterised in that the pharmaceutical composition of described reducing blood lipid includes parts by weight of raw materials
100~300 parts of raw hawthorn, 100~200 parts of raw sangqi ginseng, 50~150 parts of Radix Polygoni Multiflori, through pre-treatment, extract and post processing step
Suddenly prepare.
2. the pharmaceutical composition of reducing blood lipid according to claim 1, it is characterised in that the drug regimen of described reducing blood lipid
Thing includes 100~300 parts of raw hawthorn, 100~200 parts of raw sangqi ginseng, 50~150 parts of the Radix Polygoni Multiflori, premenstrual place of parts by weight of raw materials
Reason, extraction and post-processing step are prepared.
3. the preparation method of the pharmaceutical composition of the reducing blood lipid described in a kind of claim 1 or 2, it is characterised in that including preceding place
Reason, extraction and post-processing step, specifically include：
A, selected and clean bulk drug, are then uniformly mixed so as to obtain material a standby by formulation ratio weighing bulk drug；
B, alcohol solution dipping 7~10 days will be added in material a, be filtrated to get filtrate b and filter residue c；
C, the water of 8~12 times of filter residue c weight will be added to boil in filter residue c carry 3~4 times, every time 0.5~1.5h, merging filtrate, concentration
Obtain thick paste d；
D, filtrate b is concentrated to give thick paste e, thick paste d and thick paste e are well mixed, drying and crushing sieving obtains object drop blood
The pharmaceutical composition of fat.
4. preparation method according to claim 3, it is characterised in that the volume basis of the ethanol solution described in step B are dense
Spend is 60~80%.
5. the preparation method according to claim 3 or 4, it is characterised in that the concentration expressed in percentage by volume of described ethanol solution is
70%.
6. preparation method according to claim 3, it is characterised in that the temperature soaked in step B is 20~40 DEG C.
7. preparation method according to claim 3, it is characterised in that pulverizing and sieving described in D steps is to crush 200
Mesh sieve.
8. the preparation of the pharmaceutical composition of the reducing blood lipid described in a kind of claim 1 or 2, it is characterised in that described reducing blood lipid
Tablet, powder, capsule, granule and pill prepared by pharmaceutically acceptable auxiliary material are added in pharmaceutical composition.
9. the application of the pharmaceutical composition of the reducing blood lipid described in a kind of claim 1 or 2, it is characterised in that described reducing blood lipid
Application of the pharmaceutical composition in blood lipid-lowering medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710156866.5A CN106890225A (en) | 2017-03-16 | 2017-03-16 | A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710156866.5A CN106890225A (en) | 2017-03-16 | 2017-03-16 | A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106890225A true CN106890225A (en) | 2017-06-27 |
Family
ID=59192224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710156866.5A Pending CN106890225A (en) | 2017-03-16 | 2017-03-16 | A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106890225A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669760A (en) * | 2017-09-04 | 2018-02-09 | 郑州海斯威生物技术有限公司 | A kind of blood-fat reducing composition and application thereof and compound preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109353A (en) * | 1994-03-31 | 1995-10-04 | 徐祖德 | Prescription for defatting and hypotensor capsule and its making method |
| CN1785284A (en) * | 2004-12-10 | 2006-06-14 | 天津天士力制药股份有限公司 | Medicinal composition containing flowery knotwood root |
| CN102225107A (en) * | 2011-06-22 | 2011-10-26 | 河南省中医药研究院 | Yixin xuezhikang capsule |
-
2017
- 2017-03-16 CN CN201710156866.5A patent/CN106890225A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109353A (en) * | 1994-03-31 | 1995-10-04 | 徐祖德 | Prescription for defatting and hypotensor capsule and its making method |
| CN1785284A (en) * | 2004-12-10 | 2006-06-14 | 天津天士力制药股份有限公司 | Medicinal composition containing flowery knotwood root |
| CN102225107A (en) * | 2011-06-22 | 2011-10-26 | 河南省中医药研究院 | Yixin xuezhikang capsule |
Non-Patent Citations (2)
| Title |
|---|
| 杨爱萍等: "山楂、丹参、三七合用调节血脂作用的实验研究", 《达能营养中心第十三届年会》 * |
| 赵桂芳等: "血脂异常中成药配伍规律研究", 《世界科学技术-中医药现代化 中药研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669760A (en) * | 2017-09-04 | 2018-02-09 | 郑州海斯威生物技术有限公司 | A kind of blood-fat reducing composition and application thereof and compound preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN108926702A (en) | A kind of Chinese herbal medicine formula and preparation method thereof for conditioning subhealth state | |
| CN105497620A (en) | Health-care traditional Chinese medicine preparation for weight reduction and body building | |
| CN104758404A (en) | Three-snake powder composition for treating autoimmune diseases, and preparation method thereof | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN103230486B (en) | Traditional Chinese medicine composition, preparation method thereof, and application thereof in preparing medicines used for treating fatty liver | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN103432391A (en) | Medicament for treating hyperlipemia and preparation method thereof | |
| CN106890225A (en) | A kind of pharmaceutical composition of reducing blood lipid and preparation method thereof, preparation and application | |
| CN104225067B (en) | Chinese medicine composition, preparation method and purposes for treating postmenopausal osteoporosis | |
| CN106913626B (en) | A kind of pharmaceutical composition for treating enterogastritis and preparation method thereof, preparation and application | |
| CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN101732657A (en) | Medicine composition | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN108671055A (en) | A kind of Chinese medicine composition of spleen tonifying and fat and preparation method thereof | |
| CN108497383A (en) | A kind of traditional Chinese medicine health care preparation with fat-eliminating antihypelipidemic effect | |
| CN107440118A (en) | A kind of health food with defecating feces excretion and preparation method thereof | |
| CN106880794A (en) | A kind of digestion-promoting spleen-invigorating umbilical therapy paste and preparation method thereof | |
| CN106729191A (en) | A kind of preparation method and application of umbilical therapy paste | |
| CN109200183A (en) | A kind of herbal composite and preparation method thereof and product | |
| CN106173604A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Rhizoma Polygonati Odorati |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170627 |